PSS54 EVALUATION OF TREATMENT SATISFACTION WITH ETANERCEPT VERSUS ALTERNATIVE TREATMENTS FOR PSORIASIS: A PATIENT SURVEY ACROSS NINE EUROPEAN COUNTRIES  by Conway, P et al.
(OR = 0.94, IC95%: 0.88–0.99). CONCLUSIONS: Parents/
caregivers have serious worries to use corticosteroids in chil-
dren with ﬂares in face/neck, with mild severity and in younger
childrens.
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OBJECTIVES: Alternative treatments are available to relieve
people with moderate and severe psoriasis in states of remission
and relapse. The purpose of this study was characterise treat-
ment satisfaction with alternative therapies in a survey across
nine European countries. Speciﬁcally, to determine relative
treatment satisfaction with etanercept. METHODS: Up to 120
subjects with moderate or severe psoriasis were identiﬁed in
each of nine countries: Austria (n = 50), France (n = 120),
Germany (n = 120), Italy (n = 120), The Netherlands (n = 75),
Norway (n = 43), Spain (120), Sweden (n = 50) and the UK
(n = 120). Patients were identiﬁed through their dermatologist,
and selected in order to give a sample that represented the alter-
native current treatment regimens, including: biologics such as
etanercept, systemic therapies, and light therapy (PUVA).
Patients were excluded if they had psoriatic arthritis. Treatment
severity was classiﬁed in two ways. Firstly, self-reported sever-
ity, and secondly; percent bodily coverage with psoriatic
plaques. Satisfaction with treatment was deﬁned as a response
of either “satisﬁed” or “very satisﬁed” with treatment. Treat-
ments were excluded from the analysis where <20 observations
were available. Fumaderm was excluded as it was not relevant
for all countries. RESULTS: There were 818 respondents in
total; 45% male. Their mean age was 40.1 years (sd 11.8), and
the median time since diagnosis was 12.0 years (IQR 4.0 to
21.0). The frequency of psoriasis severity for people with <3%,
3%–10%, and >10% bodily coverage was 74 (9%), 421
(52%), and 323 (39%) people, respectively. Overall, 67% of
people expressed satisfaction with psoriasis treatment (64%
moderate and 71% severe; p = 0.117). For people with moder-
ate psoriasis, 3% to 10% coverage, the following percent of
people reported satisfaction with treatment: cyclosporine 60%
(52 of 87), PUVA 63% (54 of 86), methotrexate 65% (53 of
81) and etanercept 78% (21 of 27; p = 0.387). For people with
severe psoriasis, >10% coverage, treatment satisfaction was
achieved as follows: methotrexate 59% (31 of 53), PUVA 62%
(28 of 45), cyclosporine 70% (19 of 27), remicade 71% (20 of
28) and etanercept 94% (46 of 49; p = 0.001). People with
severe psoriasis were more satisﬁed with treatment with etan-
ercept than moderate psoriasis (78% vs. 94%; p = 0.088).
These ﬁndings were consistent across the nine countries. CON-
CLUSIONS: The majority of people with moderate and severe
psoriasis expressed satisfaction with their current treatment.
Treatment satisfaction with etanercept in both groups was
more frequent when using etanercept (78% and 94%,
respectively).
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OBJECTIVES: To examine ustekinumab’s effects on work limi-
tations, productivity, and the number of workdays missed due to
psoriasis. METHODS: In PHOENIX 2 (a Phase 3 trial), 1,230
patients were randomized 1:1:1 to ustekinumab (45 mg or 90 mg
administered at weeks 0, 4, and q12 weeks), or placebo. Patients
randomized to placebo crossed over to receive ustekinumab
45 mg or 90 mg at week 12. Work limitations were assessed
using the Work Limitations Questionnaire (WLQ). WLQ assesses
work limitations due to health in four areas: physical, time
management, mental-interpersonal, and output demands. Each
demand is scored from 0 (limited none of the time) to 100
(limited all of the time). Productivity was assessed using a Visual
Analog Scale (0–10). The number of workdays missed due to
psoriasis in the last 4 weeks was evaluated at baseline and week
12. RESULTS: At baseline, 75% of patients were employed. At
week 12, the mean changes in scores of physical, time manage-
ment, mental-interpersonal, and output demands were -6.33,
-7.85, -7.67 and -6.09, respectively, in ustekinumab-treated
patients, compared to mean changes of -0.20, 0.74, 1.11, and
1.08, respectively, in the placebo group (p < 0.01, each compari-
son of ustekinumab vs. placebo). The mean change in produc-
tivity score from baseline to week 12 was -2.55 for the combined
ustekinumab group vs 0.0 for the placebo group (p < 0.001). The
mean reduction from baseline to week 12 in the number of
workdays missed in the last 4 weeks in the combined usteki-
numab group was 0.2 days, compared to a reduction of 0.04
days in the placebo group. On an annual basis, this represents a
reduction of 2.1 workdays missed in the ustekinumab group vs.
the placebo group. Patients in the placebo group who crossed
over to ustekinumab at week 12 achieved similar improvements
at week 24 in work limitations, productivity, and workdays
missed compared to patients initially randomized to usteki-
numab. CONCLUSIONS: Ustekinumab signiﬁcantly improved
work limitations, increased productivity, and reduced workday
loss in moderate to severe psoriasis patients.
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OBJECTIVES: Reﬁll adherence to medications and health care
costs are important factors to consider while making informed
decision regarding treatment of rosacea patients. The objective of
this study was to examine predictors of number of reﬁlls related
to topical metronidazole and total health care costs in rosacea
patients. METHODS: This study utilized a longitudinal cohort
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